Preoperative and Postoperative Management of Lung Transplantation Patient

서울대학교 의과대학 흉부외과

한 성 구

1. Managemant of Donor

1-1 Selection of donor

- (a) Age \(55
- (b) Normal chest x-ray just before harvest should be checked every 8 hrs chest x-ray less than 2 hrs old should be available at time of procurement minimal abnormality never should be regarded as non-significant
- (c) PaO2 >300mmHg on Fi02=1.0, PEEP=5 cmH20 should be checked at 6-8 hr interval following trends is important
- (d) Normal bronchoscopic exam immediately prior to explant check for purulent secretion or foreign body blood in the airways: suspicion of associated pneumonitis
- (e) Absence of infected sputum culture usually not available at time of explant tracheal aspirate 15 PMN/x400 presence of heavy Candida is contraindication
- (f) No previous thoracic surgery on the side of harvest
- (g) No significant chest trauma or lung contusion
- (h) Negative for serum HIV and HBsAg
- * Smoking History is not a contraindication

1-2 Management of Donor

- * keep "dry": CVP or PCWP \(10mmHg
- * intubation and mechanical ventilation

PEEP 5 cmH20, VT 15ml/kg, PIP < 20cmH20 Frequent sigh

- * heparinization 25000U IV 1/2-1 hr before harvest
- * PGE1 500mg/15-20ml N/S infusion to pulmonary artery or IV 10-20 min before harvest
- * Ceftazidime + Clindamycin

2. Donor-Recipient Match

* ABO Blood Type:

Type O is NOT the universal donor

* HLA Type

Usually not known at time of transplantation

* Size : matched by predicted donor and recipient lung volume

Oversized allograft: compressive atelectasis cardiac tamponade

SLT for emphysema pt: can adopt oversized allograft up to $20\,\%$

BLT for IPF pt: undersized allograft(20%) is desirable

* CMV status

CMV (-)donor for CMV (-)recipient

- * HBsAg status
- 3. Selection of Recipient

End stage lung disease with

(a) Expected survival less than 18 months

- (b) Age < 60
- (c) No active pulmonary or extrapulmonary infection
- (d) No significant coronary artery disease
- (e) Not on high-dose steroid
- (f) Adequate nutrition and ambulatory
- (g) No previous major abdominal or thoracic surgery
- (h) Psychologically stable

4. Timing for Lung Transplantation

4-1 COPD

- * Postbronchodilator FEV1 \(30\% Predicted \)
- * Resting Hypoxemia \(55-60 \text{ mmHg} \)
- * Hypercapnia
- * Significant Secondary Pulmonary Hypertension
- * Clinical Course

Declin of FEV1

Life-Threatening Exacerbation

4-2 DILD

- * VC, TLC < 60% Predicted
- * Resting Hypoxemia
- * Significant Secondary Pulmonary Hypertension
- * Clinical, Radiologic, Physiologic Score > 60 after 6 mos Tx

4-3 PPH

- * NYHA Class II or IV
- * Mean Rt. Atrial Pressure > 10mmHg
- * Mean Pulmonary Artery Pressure > 50mmHg
- * Cardiac Index < 2.5/min/m2

5. Pre-transplantation Evaluation of Recipient

Pulmonary Function

Standard PFT with ABGA

Quantitative Ventilation-Perfusion Lung Scan

Cardiopulmonary Exercise Test

Chest CT*

Cardiac Evaluation

Radionuclide Ventriculography

Doppler Echocardiography with Saline Test

Right Heart Catheterization

Left Heart Catheterization and Coronary Angiography*

Transesophageal Echocardiography*

Others

ABO Typing

HLA Typing and Panel of Reactive Antibodies (PRA)

Serology for Hepatitis A, B and C: HIV: CMV

Psychosocial Evaluation

6. Immunosuppressive Treatment

7. Immediate Post-op. Care

7-1 General post-op care

(1) Ventilator

Tidal volume:12ml/kg, Rate: 12-14/min

PEEP: usually 5-7.5cm H20 (NOT in SLT for COPD)

(2) PGE1

between 0.01-0.1 μ g/kg/min

starts intra-op.(at least 15 min before clamping pul-

monary artery)

(3) Physiotherapy

starts 12 hrs post-op

(4) Others

Dopamin 3 µg/kg/min

Maintain diastolic BP \(\) 80mmHg

Ketoconazole to increase CSA blood level

7-2 Prophylaxis for infection

(1) Antibiotics

cefazoline pre-op

Ceftazidime + Vancomycin post-op

Change according to sputume culture or D/C in 7-10d

(2) Acyclovir

200mg bid po

First 6 MOS

(3) Trimethoprim-Sulfamethoxazole (Bactrim)

Start day 21, 2T bid

6-1 Immuosuppressive regimen: Induction

DRUGS	REGIMEN
Cyclosporine	2-4 mg/hr IV drip immediate post-op.(50mg/50ml)
	Daily monitor blood level
	Switch to oral in several days (bioequivalent oral dose:3-4 times of ${\rm I\!V}$ dose)
Azathioprine	2mg/kg IV immediate PRE-op.
	2mg/kg/d(100-125mg) po. Start 12 hrs post-op.
Corticosteroid	Methylprednisolone 1g IV INTRA-op, before reperfusion
	Methylprednisolone 1mg/kg/d IV for 3 days
	IV methylprednisolone or oral prednisolone 0.5mg/kg/d
ALG	10-15mg/kg/d IV for first 5-7 days
	Skin test: 0.1ml of 1:1000 dilution intradermally
	Premedication with tylenol (650mg)and benadryl(50mg)
	Stop if platelet < 50K or WBC < 4000

6-2 Immunosuppressive Regimen: Maintenence

DRUGS	REGIMEN
Cyclosporine	Titrate dose according to blood level
	5-6mg/kg bid (300mg/300mg)initially
	Trough blood level 350-400 ng/ml to 8 wks
	300-350 ng/ml 8-12 wks
	300 ng/ml 3-6 mos
	250-300 ng/ml 6 mos-lyr
	185-225 ng/ml after 1yr
Azathioprine	2mg/kg/d
	Increase dose to 2.5-3mg/kg/d if rejection(+)
	Decrease dose if WBC < 4000/ml
Prednisone	0.5mg/kg/d for first 3 mos
	Taper to 15mg/d by 6mos then to 15mg/d qod by 1yr

Life long M-W-F protocol

4) Gancyclivir

CMV (-) recipient with CMV (+) donor

CMV (+) recipient

Post-op 3-12 wks

5) INH

Complete With CMV (+) donor

Should be given to all Korean recipient

400 mg/d, life-long

5mg/kg IV twice a day for 7 days,
then 5mg/kg once a day x5/wk

6) Nystatin

At lease for 3 month

8. Surveillance

 PFT weekly for postop. 3 months monthly for 1 year every 2-3 months life-long

Check FEV1 everyday home with portable spirometer

Notify Dr. if decrease more than 10% for 3 days

TBLB
 2-3 week after transplantation
 F/U in 8-12 week, 6 month, 1 year then annually